Belgium
-
◆ Last euro syndication for 2025, done ◆ Good timing as usual ◆ Book is one of sovereign’s largest -
◆ €1.7bn deal gets 2025 funding past the line ◆ Seven year print and 18 year social tap ◆ Bankers say market gives 'good results' and more supply inbound
-
Belgian family company is buying Délifrance and a business from Bunge
-
◆ Arbitrage attracts Belgium to dollars again ◆ No book updates ‘a little surprising’ and ‘a red flag’ ◆ Investors expected more spread
-
◆ New €5bn line opened against ‘not easy’ backdrop ◆ Planned long-end OLO turned out to be 2042 ◆ Flexibility once again serves sovereign well
-
◆ Bond tightens 5bp from guidance ◆ Highest subscribed deal so far this week ◆ Relative value highlights issuer as 'strongest' Belgian region
-
Belgian pharmaceutical company has made three acquisitions this year
-
◆ Large size ◆ Pricing ‘on the money’ ◆ Getting squeezy versus OATs
-
◆ Deal four times covered ◆ Walloon used as reference ◆ Higher than average tightening
-
The facility's ESG features will be finalised before the end of the year
-
◆ Book supports large deal despite attrition ◆ Belgian scarcity makes finding fair value tricky ◆ 1.5 day execution chosen to aid price discovery
-
No competition expected as investors hunger for covered paper across the curve
